Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

Open access
Weber, Jeffrey, Sondak, Vernon K., Scotland, Ronaldo, Phillip, Ramila, Wang, Flora, Rubio, Valerie, Stuge, Tor B., Groshen, Susan G., Gee, Conway, Jeffery, Georgia G., Sian, Shirley, Lee, Peter P.·2003·Cancer

Abstract

BACKGROUND: Forty‐eight patients with resected Stages IIA and IIB melanoma were immunized with two tumor antigen epitope peptides derived from gp100 209–217 (210M) (IMDQVPSFV) and tyrosinase 368–376 (370D) (YMDGTMSQV) emulsified with incomplete Freund's adjuvant (IFA). Patients were assigned randomly to receive either peptides/IFA alone or with 250 μm of granulocyte‐macrophage–colony‐stimulating factor (GM‐CSF) subcutaneously daily for 5 days to evaluate the toxicities and immune responses in either arm. Time to recurrence and survival were secondary end points. METHODS: Immunizations were administered every 2weeks × 4, then every 4 weeks × 3, and once 8 weeks later. A leukapheresis to obtain peripheral blood mononuclear cells for immune analyses and skin testing with peptides and recall reagents was performed before and after eight vaccinations. RESULTS: Local pain and granuloma formation, fever, and lethargy of Grade 1 or 2 were observed. Transient vaccine‐related Grade III and no Grade IV toxicity was observed. Seventeen of the 40 patients for whom posttreatment skin tests were performed developed a positive skin test response to the gp100 peptide, but only 1 of the 40 patients developed a positive skin test response to tyrosinase. Immune responses were measured by release of interferon‐gamma (IFN‐γ) in an enzyme‐linked immunosorbent assay (ELISA) by effector cells in the presence of peptide‐pulsed antigen‐presenting cells, by cytokine release of IFN‐γ, GM‐CSF, and tumor necrosis factor‐alpha in a Luminex assay, or by an antigen‐specific tetramer flow cytometry assay. Thirty‐four of the 39 patients for whom the ELISA data were performed demonstrated an immune response after vaccination, as did 37 of 42 patients by tetramer assay. Enzyme‐linked immunosorbent assay, Luminex, and tetramer responses in the GM‐CSF/peptide/IFA group were higher than in the peptide/IFA group. Epitope spreading to the MART‐1/MelanA 27‐35 and 26‐35 (27L) epitopes was detected by tetramer assay in 10 patients. Seven of 48 patients experienced disease recurrence with a median of 24 months of follow‐up and 2 patients in this intermediate to high risk group have died. CONCLUSION: These data suggest a significant number of patients with resected melanoma mount an antigen‐specific immune response against a peptide vaccine. There is a trend for GM‐CSF to modestly increase the immune response and support further development of GM‐CSF as a vaccine adjuvant. Cancer 2003;97:186–200. © 2003 American Cancer Society. DOI 10.1002/cncr.11045

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.11045

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 173

Metadata

Authors
Weber, J., Sondak, V. K., Scotland, R., Phillip, R., Wang, F., Rubio, V., Stuge, T. B., Groshen, S. G., Gee, C., Jeffery, G. G., Sian, S., & Lee, P. P.
Venue
Cancer
Publisher
Wiley
Published
2002-12-18
Volume
97
Issue
1
Pages
186-200
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2036961863
Cited by
173
References
1
FWCI
6.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. https://app.cochat.ai/papers/10.1002/cncr.11045
The paper
Weber, J., Sondak, V. K., Scotland, R., Phillip, R., Wang, F., Rubio, V., Stuge, T. B., Groshen, S. G., Gee, C., Jeffery, G. G., Sian, S., & Lee, P. P. (2003). Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. https://doi.org/10.1002/cncr.11045

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.